The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / RA Patients on DMARDs Have Higher Risk of Infection

RA Patients on DMARDs Have Higher Risk of Infection

November 3, 2015 • By Richard Quinn

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Drugs_500x270Researchers found that patients with rheumatoid arthritis (RA) on a non-biologic disease modifying anti-rheumatic drug (DMARD) have triple the risk of developing a serious infection vs. the general population. This should serve as a reminder to “better use the tools at our disposal,” says one expert.

You Might Also Like
  • Higher Fracture Risk in Patients with Polymyalgia Rheumatica, Giant-Cell Arteritis
  • Denosumab Does Not Increase Risk of Infection in RA Patients
  • Cardiovascular Disease Mortality Risk Remains Higher for Patients with RA
Also By This Author
  • What’s Driving the Pain? Alternative Approaches to Pain Management

In work presented this summer at the European League Against Rheumatism Annual European Congress of Rheumatology, Swedish researchers reported that patients treated with a non-biologic DMARD had a 6.1% risk of developing a serious infection.1 A 2.2% risk was observed for the general population. The study was based on 12,128 patients participating in the Swedish National Patient Register and the National Prescription Drug Register.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In an email interview with The Rheumatologist, Jinoos Yazdany, MD, MPH, a rheumatologist at the University of California at San Francisco (UCSF), who has written about DMARD costs, says the Swedish results would likely be the same in the U.S.

“DMARDs are important for halting joint damage and improving quality of life in RA,” she says. “I don’t think this study should dissuade patients from starting or switching therapy. Instead, we need to better use the tools at our disposal to prevent infections. For example, all patients receiving immunosuppression should receive pneumococcal and influenza vaccination.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

According to news coverage of the study, the Swedish research team, led by Elizabeth Arkema, ScD, also reported “that six of every 100 patients with RA who switched to a different [non-biologic] DMARD were hospitalized with an infection within one year of new treatment initiation, whereas the risk for a serious infection in the general population remained constant over time.”1

Dr. Yazdany believes more research is needed to address why infection risks may increase for patients switching therapies.

“This may be the effect of a population of RA patients who has more active disease and perhaps more medical comorbidities, putting them at risk for infection,” she says. “Alternatively, there may be an additive effect of different immunosuppressives that underlies this finding.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Richard Quinn is a freelance writer in New Jersey.

Reference

  1. Pulawski S. Risk of serious infection with non-biologic DMARD use tripled in patients with RA. Healio Rheumatology. 2015 Jun 30.

Filed Under: Conditions, Rheumatoid Arthritis

You Might Also Like:
  • Higher Fracture Risk in Patients with Polymyalgia Rheumatica, Giant-Cell Arteritis
  • Denosumab Does Not Increase Risk of Infection in RA Patients
  • Cardiovascular Disease Mortality Risk Remains Higher for Patients with RA
  • Rheumatoid Arthritis Patients on Biologics Remain At Risk of Infection

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)